Literature DB >> 23263897

Factors associated with the effectiveness of plasma exchange for the treatment of NMO-IgG-positive neuromyelitis optica spectrum disorders.

Young-Min Lim1, So Young Pyun, Bong-Hui Kang, Jimin Kim, Kwang-Kuk Kim.   

Abstract

To identify factors associated with plasma exchange response in neuromyelitis optica (NMO) spectrum disorders, the clinical and magnetic resonance imaging (MRI) features of 31 NMO-IgG-positive patients receiving plasma exchange for steroid-resistant exacerbations were analyzed. Functional improvement was observed in 65% of the patients. A lower baseline Expanded Disability Status Scale score was associated with favorable response (p = 0.040). Patients without cord atrophy had a higher success rate than patients with atrophy (p = 0.016). Levels of NMO-IgG did not differ between responders and non-responders before and after plasma exchange. In conclusion, a minimal pre-existing disability is the primary determinant of the effectiveness of plasma exchange.

Entities:  

Keywords:  Plasma exchange; neuromyelitis optica spectrum disorders; neuromyelitis optica-IgG; prognostic factors

Mesh:

Substances:

Year:  2012        PMID: 23263897     DOI: 10.1177/1352458512471875

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  14 in total

Review 1.  Neuromyelitis optica spectrum disorders associated with other autoimmune diseases.

Authors:  Eduardo Freitas; Joana Guimarães
Journal:  Rheumatol Int       Date:  2014-06-22       Impact factor: 2.631

2.  Plasma Exchange in a Patient with Tumefactive, Corticosteroid-Resistant Multiple Sclerosis.

Authors:  Kristin M Ikeda; Donald H Lee; J Alexander Fraser; Seyed Mirsattari; Sarah A Morrow
Journal:  Int J MS Care       Date:  2015 Sep-Oct

3.  Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange.

Authors:  Hesham Abboud; Alex Petrak; Maureen Mealy; Sarana Sasidharan; Laila Siddique; Michael Levy
Journal:  Mult Scler       Date:  2015-04-28       Impact factor: 6.312

Review 4.  Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials.

Authors:  Sean J Pittock; Anastasia Zekeridou; Brian G Weinshenker
Journal:  Nat Rev Neurol       Date:  2021-10-28       Impact factor: 42.937

Review 5.  Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders.

Authors:  Ingo Kleiter; Ralf Gold
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 6.  Neuromyelitis optica: clinical features, immunopathogenesis and treatment.

Authors:  S Jarius; B Wildemann; F Paul
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

Review 7.  Immunotherapy of neuromyelitis optica.

Authors:  Benjamin Bienia; Roumen Balabanov
Journal:  Autoimmune Dis       Date:  2013-12-25

Review 8.  Cell-surface central nervous system autoantibodies: clinical relevance and emerging paradigms.

Authors:  Sarosh R Irani; Jeffrey M Gelfand; Adam Al-Diwani; Angela Vincent
Journal:  Ann Neurol       Date:  2014-07-10       Impact factor: 10.422

9.  Safety and efficacy of plasma exchange for the treatment of optic neuritis in neuromyelitis optica spectrum disorders: A protocol for systematic review and meta-analysis.

Authors:  Mengyu Han; You Chen; Luqi Nong; Ziqiang Liu; Lu Hao; Zhijun Wang
Journal:  Medicine (Baltimore)       Date:  2020-07-10       Impact factor: 1.817

10.  Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions.

Authors:  Ingo Kleiter; Anna Gahlen; Nadja Borisow; Katrin Fischer; Klaus-Dieter Wernecke; Kerstin Hellwig; Florence Pache; Klemens Ruprecht; Joachim Havla; Tania Kümpfel; Orhan Aktas; Hans-Peter Hartung; Marius Ringelstein; Christian Geis; Christoph Kleinschnitz; Achim Berthele; Bernhard Hemmer; Klemens Angstwurm; Jan-Patrick Stellmann; Simon Schuster; Martin Stangel; Florian Lauda; Hayrettin Tumani; Christoph Mayer; Markus Krumbholz; Lena Zeltner; Ulf Ziemann; Ralf Linker; Matthias Schwab; Martin Marziniak; Florian Then Bergh; Ulrich Hofstadt-van Oy; Oliver Neuhaus; Uwe K Zettl; Jürgen Faiss; Brigitte Wildemann; Friedemann Paul; Sven Jarius; Corinna Trebst
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2018-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.